The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

Also called NCT05371366

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05371366
Other papers using this trial's data
  • Comparison of a Novel Occluder Versus Traditional Occluder in Atrial Septal Defect: A Randomized Trial Journal of the American Heart Association, 2026-10-06 DOI, PubMed 42757893
  • Device endothelialization and morphology assessments at 1 year using computed tomography angiography: comparison of traditional with novel puncturable atrial septal defect occluders BMC cardiovascular disorders, 2024-12-30 DOI, PubMed 39734195, PMC11684296 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05371366. Randomized; no masking; primary purpose treatment. Start 2022-04-22 (actual); primary completion 2023-04-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)
Condition
Atrial Septal Defect
Intervention (Device)
ASD closure with the novel occluder (ReAces)
Intervention (Device)
ASD closure with normal occluder
Lead sponsor
Shanghai Zhongshan Hospital (class: other)

Record details

Record id
cardio:ct-nct05371366
Content hash
c6feea3bac7084949875adb9bccbd7a35611c26d13f34e423980e013949eb45e